Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

BC-101

Cell therapy (Stem-cell derived) · developed by Bright Cell

Phase 1 Most advanced trial

DRUG Developer

1 Registered trials

What is BC-101?

BC-101 is a suspension of human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) being studied for the treatment of nasolabial fold wrinkles.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (Stem-cell derived)
Therapy area: Dermatology
Developer: Bright Cell, Inc. (DRUG)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05162326	Phase 1	Nasolabial Fold Wrinkles	Not yet recruiting	DRUG

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nasolabial Fold Wrinkles

More from Bright Cell

BMB-101 Phase 2 BPT567 Phase 1 YB-1113 Phase 1

Sources

ClinicalTrials.gov NCT05162326

Updated Oct 3, 2026. Something wrong or missing? Report it on the DRUG page.

Follow DRUG, the company behind BC-101

See DRUG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DRUG catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z